{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T03:10:46Z","timestamp":1793502646947,"version":"4.5.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100018537","name":"National Science and Technology Major Project","doi-asserted-by":"publisher","award":["2023ZD0502100"],"award-info":[{"award-number":["2023ZD0502100"]}],"id":[{"id":"10.13039\/501100018537","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ijrobp.2025.06.3857","type":"journal-article","created":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T19:21:38Z","timestamp":1750879298000},"page":"296-304","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Risk-Based Local Radiation Therapy in Oligometastatic Non-small Cell Lung Cancer in the Era of Immunotherapy: A Multicentric Cohort Study"],"prefix":"10.1016","volume":"124","author":[{"given":"Jinghao","family":"Duan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingming","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiyao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianzhong","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7201-2930","authenticated-orcid":false,"given":"Nan","family":"Bi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2025.06.3857_bib0001","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ijrobp.2025.06.3857_bib0002","first-page":"47","article-title":"Cancer incidence and mortality in China, 2022","volume":"4","author":"Han","year":"2024","journal-title":"J Natl Cancer Cent"},{"key":"10.1016\/j.ijrobp.2025.06.3857_bib0003","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/S1470-2045(19)30718-1","article-title":"Characterisation and classification of oligometastatic disease: A European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation","volume":"21","author":"Guckenberger","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2025.06.3857_bib0004","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1093\/jnci\/djac015","article-title":"Randomized trial of first-line tyrosine kinase inhibitor with or without radiotherapy for synchronous oligometastatic EGFR-mutated non-small cell lung cancer","volume":"115","author":"Wang","year":"2023","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ijrobp.2025.06.3857_bib0005","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1200\/JCO.20.00818","article-title":"Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: Long-term results of the SABR-COMET phase II randomized trial","volume":"38","author":"Palma","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.06.3857_bib0006","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1016\/S1470-2045(16)30532-0","article-title":"Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: A multicentre, randomised, controlled, phase 2 study","volume":"17","author":"Gomez","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2025.06.3857_bib0007","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1200\/JCO.19.00201","article-title":"Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: Long-term results of a multi-institutional, phase II, randomized study","volume":"37","author":"Gomez","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.06.3857_bib0008","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.3501","article-title":"Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: A phase 2 randomized clinical trial","volume":"4","author":"Iyengar","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijrobp.2025.06.3857_bib0009","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1200\/JCO.18.00149","article-title":"Updated analysis of KEYNOTE-024: Pembrolizumab versus platinum-based chemotherapy for advanced non\u2013small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater","volume":"37","author":"Reck","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.06.3857_bib0010","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1200\/JCO.22.01989","article-title":"Pembrolizumab plus pemetrexed and platinum in nonsquamous non-small-cell lung cancer: 5-year outcomes from the phase 3 KEYNOTE-189 study","volume":"41","author":"Garassino","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.06.3857_bib0011","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1200\/JCO.22.01990","article-title":"Pembrolizumab plus chemotherapy in squamous non\u2013small-cell lung cancer: 5-year update of the phase III KEYNOTE-407 study","volume":"41","author":"Novello","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.06.3857_bib0012","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S1470-2045(20)30641-0","article-title":"First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): An international, randomised, open-label, phase 3 trial","volume":"22","author":"Paz-Ares","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2025.06.3857_bib0013","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus ipilimumab in advanced non-small-cell lung cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2025.06.3857_bib0014","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1001\/jamaoncol.2019.1449","article-title":"Pembrolizumab after completion of locally ablative therapy for oligometastatic non-small cell lung cancer: A phase 2 trial","volume":"5","author":"Bauml","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijrobp.2025.06.3857_bib0015","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1001\/jamaoncol.2019.1478","article-title":"Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer: Results of the PEMBRO-RT phase 2 randomized clinical trial","volume":"5","author":"Theelen","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijrobp.2025.06.3857_bib0016","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S1470-2045(21)00658-6","article-title":"Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: An open-label, multicentre, randomised, phase 2 trial","volume":"23","author":"Schoenfeld","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2025.06.3857_bib0017","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001001","article-title":"Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: A randomized phase I\/II trial","volume":"8","author":"Welsh","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ijrobp.2025.06.3857_bib0018","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1200\/JCO.23.02075","article-title":"Thoracic radiotherapy improves the survival in patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer treated with epidermal growth factor receptor-tyrosine kinase inhibitors: A multicenter, randomized, controlled, phase III trial","volume":"43","author":"Sun","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.06.3857_bib0019","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1186\/s12885-020-06876-4","article-title":"Stereotactic ablative radiotherapy for the comprehensive treatment of 1-3 oligometastatic tumors (SABR-COMET-3): Study protocol for a randomized phase III trial","volume":"20","author":"Olson","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ijrobp.2025.06.3857_bib0020","doi-asserted-by":"crossref","first-page":"8506","DOI":"10.1200\/JCO.2024.42.16_suppl.8506","article-title":"NRG-LU002: Randomized phase II\/III trial of maintenance systemic therapy versus local consolidative therapy (LCT) plus maintenance systemic therapy for limited metastatic non-small cell lung cancer (NSCLC)","volume":"42","author":"Iyengar","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.06.3857_bib0021","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1007\/s00432-021-03849-3","article-title":"Efficacy of single-site radiotherapy plus PD-1 inhibitors vs PD-1 inhibitors for oligometastatic non-small cell lung cancer","volume":"148","author":"Wang","year":"2022","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.06.3857_bib0022","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.cllc.2020.06.010","article-title":"Immune-related adverse events of pembrolizumab in a large real-world cohort of patients with NSCLC with a PD-L1 expression \u2265 50% and their relationship with clinical outcomes","volume":"21","author":"Cortellini","year":"2020","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.ijrobp.2025.06.3857_bib0023","article-title":"Biomarkers of checkpoint inhibitor induced immune-related adverse events-a comprehensive review","volume":"10","author":"Hommes","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.ijrobp.2025.06.3857_bib0024","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: Epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.06.3857_bib0025","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ijrobp.2021.09.027","article-title":"A story of hypofractionation and the table on the wall","volume":"112","author":"Timmerman","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.06.3857_bib0026","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ijrobp.2025.06.3857_bib0027","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.jaad.2012.02.010","article-title":"Grading dermatologic adverse events of cancer treatments: The common terminology criteria for adverse events version 4.0","volume":"67","author":"Chen","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ijrobp.2025.06.3857_bib0028","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v065.i03","article-title":"simPH: An R package for illustrating estimates from cox proportional hazard models including for interactive and nonlinear effects","volume":"65","author":"Gandrud","year":"2015","journal-title":"J Stat Softw"},{"key":"10.1016\/j.ijrobp.2025.06.3857_bib0029","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1200\/JCO-24-02347","article-title":"De-escalation strategies with immune checkpoint blockers in non-small cell lung cancer: Do we already have enough evidence?","volume":"43","author":"Remon","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.06.3857_bib0030","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.jtho.2020.03.028","article-title":"Atezolizumab in combination with carboplatin and nab-paclitaxel in advanced squamous NSCLC (IMpower131): Results from a randomized phase III trial","volume":"15","author":"Jotte","year":"2020","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ijrobp.2025.06.3857_bib0031","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.jtho.2020.11.025","article-title":"Atezolizumab plus chemotherapy for first-line treatment of nonsquamous NSCLC: Results from the randomized phase 3 IMpower132 trial","volume":"16","author":"Nishio","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ijrobp.2025.06.3857_bib0032","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.jtho.2021.09.014","article-title":"IMpower150 final exploratory analyses for atezolizumab plus bevacizumab and chemotherapy in key NSCLC patient subgroups with EGFR mutations or metastases in the liver or brain","volume":"17","author":"Nogami","year":"2022","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ijrobp.2025.06.3857_bib0033","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S2213-2600(20)30391-X","article-title":"Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: A pooled analysis of two randomised trials","volume":"9","author":"Theelen","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.ijrobp.2025.06.3857_bib0034","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109976","article-title":"What is the predictive value of RECIST criteria following stereotactic lung radiation?","volume":"190","author":"Gulstene","year":"2024","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2025.06.3857_bib0035","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1186\/s12885-019-5977-6","article-title":"Stereotactic ablative radiotherapy for the comprehensive treatment of 4-10 oligometastatic tumors (SABR-COMET-10): Study protocol for a randomized phase III trial","volume":"19","author":"Palma","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ijrobp.2025.06.3857_bib0036","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.cllc.2016.08.002","volume":"18","author":"Swaminath","year":"2017","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.ijrobp.2025.06.3857_bib0037","doi-asserted-by":"crossref","first-page":"dju164","DOI":"10.1093\/jnci\/dju164","article-title":"Phase II study of accelerated hypofractionated three-dimensional conformal radiotherapy for stage T1-3 N0 M0 non-small cell lung cancer: NCIC CTG BR.25","volume":"106","author":"Cheung","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ijrobp.2025.06.3857_bib0038","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/S1470-2045(18)30896-9","article-title":"Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): A phase 3, open-label, randomised controlled trial","volume":"20","author":"Ball","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2025.06.3857_bib0039","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","article-title":"Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): A randomised, phase 2, open-label trial","volume":"393","author":"Palma","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2025.06.3857_bib0040","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.lungcan.2018.09.021","article-title":"Local ablative treatment for synchronous single organ oligometastatic lung cancer-A propensity score analysis of 180 patients","volume":"125","author":"Frost","year":"2018","journal-title":"Lung Cancer"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301625044992?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301625044992?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T15:42:37Z","timestamp":1771861357000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301625044992"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S0360301625044992"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2025.06.3857","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk-Based Local Radiation Therapy in Oligometastatic Non-small Cell Lung Cancer in the Era of Immunotherapy: A Multicentric Cohort Study","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2025.06.3857","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}